The discovery of these protective APOEε3 variants and elucidation of their neuroprotective mechanisms have identified novel molecular targets and therapeutic approaches for developing AD treatment strategies targeting the APOE–microglial pathway. The gene discussed is APOE; the disease is Alzheimer disease.